Get started
Author

Femke H. Burgers

Observed names: F. Burgers, F. H. Burgers, F.H. Burgers, Femke Burgers
Observed institution: The Netherlands Cancer Institute
ORCID: 0000-0002-7279-9216
Observed ORCID: 0000-0002-7279-9216
OpenAlex ID: A5048909726
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
2024 · Rik J. Verheijden, Femke H. Burgers, et al. · European Journal of Cancer · 67
PDF
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
2022 · Elizabeth A. Mittendorf, Femke Burgers, et al. · American Society of Clinical Oncology Educational Book · 51
PDF
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
2025 · Femke H. Burgers, Johannes C. K. van der Mijn, et al. · Nature Reviews Nephrology · 42
Sex differences in the pharmacokinetics of anticancer drugs: a systematic review
2024 · J. Delahousse, A.D. Wagner, et al. · ESMO Open · 40
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial
2022 · J. S. W. Borgers, F. H. Burgers, et al. · BMC Cancer · 26
PDF
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
2025 · James P Blackmur, J C Koen van der Mijn, et al. · The Lancet Oncology · 11
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
2025 · Mark Schuiveling, Laurens S Ter Maat, et al. · JNCI Journal of the National Cancer Institute · 11
PDF
Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma
2025 · Mark Schuiveling, Isabella A. J. van Duin, et al. · JAMA Oncology · 9
LBA95 Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: The randomized phase II NESCIO trial
2025 · F. Burgers, A. de Ruijter, et al. · Annals of Oncology · 8
PDF
1481TiP A prospective, randomized phase II trial of neoadjuvant immunotherapy in primary clear cell renal cancer at risk for recurrence or distant metastases: The NESCIO trial
2022 · F.H. Burgers, N.M. Graafland, et al. · Annals of Oncology · 7
1157P Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
2023 · R.J. Verheijden, J.C. Janssen, et al. · Annals of Oncology · 3
PDF
120TiP Conversion of response to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: A randomized phase Ib/IIa trial
2022 · J.S.W. Borgers, F. Burgers, et al. · Immuno-Oncology Technology · 2
PDF
36P Interpretable histomorphological subtypes linked to ICI response in advanced melanoma using AI-assisted histopathology analysis
2025 · M. Schuiveling, I. Van Duin, et al. · ESMO Real World Data and Digital Oncology · 1
AI-detected tumor-infiltrating lymphocytes for predicting outcomes in anti-PD1 based treated melanoma
2025 · Mark Schuiveling, Isabella A.J. van Duin, et al. · medRxiv · 1
PDF
AI-detected tumor-infiltrating lymphocytes and response to PD-1 based treatment in advanced melanoma.
2025 · Mark Schuiveling, Isabella A.J. van Duin, et al. · Journal of Clinical Oncology · 1
PDF
1118P Immunological alterations during neoadjuvant BRAF/MEK inhibition in patients with prior unresectable regionally advanced melanoma: Translational analysis from the REDUCTOR trial
2024 · F. Burgers, M. Rohaan, et al. · Annals of Oncology · 1
PDF
Seasonal variation of anti‐PD ‐1 outcome in melanoma—Results from a Dutch patient cohort
2023 · J. S. W. Borgers, F. H. Burgers, et al. · Pigment Cell & Melanoma Research · 1
Associations between spatial distribution of immune cell subsets and clinical outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors: results from the PUMA challenge
2026 · Mark Schuiveling, Hong Liu, et al. · Medical Image Analysis
109P The added clinical value of AI-assisted histopathology analyses in ICI response prediction in patients with advanced melanoma
2025 · M. Schuiveling, I. Van Duin, et al. · ESMO Real World Data and Digital Oncology
PDF
36International neoadjuvant kidney cancer consortium guidelines on assessing pathological response after neoadjuvant therapy in kidney cancer
2025 · James Jones, James Blackmur, et al. · The Oncologist
PDF
Body Composition Metrics and Immune Related Adverse Events in Advanced Melanoma: A Multicenter Cohort Study
2025 · Max Fernon Troenokarso, Mark Schuiveling, et al. · SSRN Electronic Journal
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
2024 · L.S. Ter Maat, I.A.J. Van Duin, et al. · medRxiv
PDF
1099P Long-term survival follow-up from the REDUCTOR trial: Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection
2023 · F.H. Burgers, S. Blankenstein, et al. · Annals of Oncology
PDF
Works count: 25
Citation count: 293
H-index: 9
I10-index: 8
Year
Topic
Type